Conatus Pharmaceuticals Inc. (CNAT)

[Inoviorulez]

Yes but there's a reason for it. Emricasan works as it was shown to have an antifibrotic effect. the reason the trial failed was because the 3 patients in the F6 group had a 100% response rate.

There's a reason for that. The problem and why it was bad luck is that when you do a liver biopsy its taken randomly off one portion of the liver. So when you use the drug it could have helped one portion of the liver, and the portion that was removed was still bad.

In any case, if you take out those 3 F6 very sick patients, the trial would have passed. Understand that the results were still good. It proved in essence that emricasan has an antifibrotic effect in fibrosis/cirrhosis which many NASH companies can't say.

Anyways now I now that the next study is going to meet its primary endpoint, because of how well it performed in the POLT-HCV trial. Hope that makes sense.